The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer

Journal of Translational Medicine

Rui-hua Xu¹  Yu-hong Li¹  Feng-hua Wang¹  Dong-sheng Zhang¹  Zhi-qiang Wang¹  Hui-yan Luo¹  Feng Wang¹  Chao Ren¹  Ying Jin¹  Wei-wei Chen¹  Miao-zhen Qiu¹  Xiao-li Wei¹ 

[1] State Key Laboratory of Oncology in South China, Department of Medical Oncology, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

关键词: Survival;    Liver metastasis;    Pancreatic cancer;    Hepatitis B virus;   

Others  :  825349
DOI  :  10.1186/1479-5876-11-249

 received in 2013-07-29, accepted in 2013-09-30,  发布年份 2013

【 摘 要 】

Background

It has been proved that hepatitis B virus (HBV) infection alters the metastatic pattern and affects survival in colorectal cancer (CRC) and hepatocellular carcinoma (HCC), while the influence of HBV infection on metastatic pattern and survival in patients with pancreatic cancer (PC) has not been investigated yet.

Methods

We conducted an investigation to evaluate the impact of HBV infection on metastatic pattern and overall survival in PC. We collected the data of 460 PC patients treated in our hospital from 1999 to 2010. Serum HBV markers were tested with enzyme-linked immunosorbent assay. The impact of HBV infection on metastatic pattern and overall survival was analyzed.

Results

We found that the incidence of synchronous liver metastasis was significantly higher in patients with HBsAg positive than those with HBsAg negative (46.0% vs 32.0%, P < 0.05), and higher in chronic HBV infection (CHB) group than both non HBV infection and resolved HBV infection group (61.1% vs 33.9%, P < 0.05, and 61.1% vs 28.7%, P < 0.05, respectively). What’s more, Kaplan-Meier analysis showed that CHB, resolved HBV infection and non HBV infection group had significant longer overall survival (OS) compared with inactive HBsAg carriers (IC) group (P=0.037, P=0.009, and P=0.019 respectively). But, in the multivariate analysis, only the CHB and non HBV infection group had significant better overall survival compared with IC group (P=0.010 and P=0.018 respectively).

Conclusions

Our study found that HBV infection increased synchronous liver metastasis rate, and HBV infection status was an independent prognostic factor in PC patients.

【 授权许可】

   
2013 Wei et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Olson SH, Kurtz RC: Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol 2013, 107:1-7.
• [2]Guo X, Cui Z: Current diagnosis and treatment of pancreatic cancer in China. Pancreas 2005, 31:13-22.
• [3]Saif MW: Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP 2007, 8:545-552.
• [4]Dehesa-Violante M, Nunez-Nateras R: Epidemiology of hepatitis virus B and C. Arch Med Res 2007, 38:606-611.
• [5]Lu FM, Li T, Liu S, Zhuang H: Epidemiology and prevention of hepatitis B virus infection in China. J Viral Hepat 2010, 17(Suppl 1):4-9.
• [6]De Mitri MS, Cassini R, Bernardi M: Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer 2010, 46:2178-2186.
• [7]Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case–control study. Clin Gastroenterol Hepatol 2007, 5:1221-1228.
• [8]Dejean A, Lugassy C, Zafrani S, Tiollais P, Brechot C: Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. J Gen Virol 1984, 65(Pt 3):651-655.
• [9]Mason A, Wick M, White H, Perrillo R: Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993, 18:781-789.
• [10]Terrier B, Cacoub P: [Hepatitis B virus, extrahepatic immunologic manifestations and risk of viral reactivation]. Rev Med Interne 2011, 32:622-627.
• [11]Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M, Abbruzzese JL: Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008, 26:4557-4562.
• [12]Ben Q, Li Z, Liu C, Cai Q, Yuan Y, Wang K, Xiao L, Gao J, Zhang H: Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: a case–control study from China. Pancreas 2012, 41:435-440.
• [13]Ulcickas YM, Quesenberry CJ, Guo D, Caldwell C, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM: Incidence of non-Hodgkin’s lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007, 46:107-112.
• [14]Engels EA, Cho ER, Jee SH: Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010, 11:827-834.
• [15]Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Lu SN, Chen CJ: Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 2010, 30:423-429.
• [16]Fiorino S, Lorenzini S, Masetti M, Deleonardi G, Grondona AG, Silvestri T, Chili E, Del PP, Bacchi-Reggiani L, Cuppini A, Jovine E: Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. Med Hypotheses 2012, 79:678-697.
• [17]Song E, Chen J, Ou Q, Su F: Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. Am J Surg 2001, 181:529-533.
• [18]Qiu HB, Zhang LY, Zeng ZL, Wang ZQ, Luo HY, Keshari RP, Zhou ZW, Xu RH: HBV infection decreases risk of liver metastasis in patients with colorectal cancer: a cohort study. World J Gastroenterol 2011, 17:804-808.
• [19]Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, Zhou H, Hao X: Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol 2009, 18:25-30.
• [20]Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y: Clinical characteristics of NonBNonC- HCC: comparison with HBV and HCV related HCC. Intervirology 2007, 50:24-31.
• [21]Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-539.
• [22]Iloeje UH, Yang HI, Chen CJ: Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int 2012, 32:1333-1341.
• [23]Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
• [24]Jin Y, Gao H, Chen H, Wang J, Chen M, Li G, Wang L, Gu J, Tu H: Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Cancer Lett 2013. http://dx.doi.org/10.1016/j.canlet.2013.03.001 webcite
• [25]Zaret KS, Grompe M: Generation and regeneration of cells of the liver and pancreas. Science 2008, 322:1490-1494.
• [26]Wandzioch E, Zaret KS: Dynamic signaling network for the specification of embryonic pancreas and liver progenitors. Science 2009, 324:1707-1710.
• [27]Chisari FV: Cytotoxic T cells and viral hepatitis. J Clin Invest 1997, 99:1472-1477.
• [28]Andus T, Bauer J, Gerok W: Effects of cytokines on the liver. Hepatology 1991, 13:364-375.
• [29]Utsunomiya T, Saitsu H, Saku M, Yoshida K, Matsumata T, Shimada M, Sugimachi K: Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Am J Surg 1999, 177:279-281.
• [30]Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y, Yuan Z: Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013, 190:5142-5151.
• [31]Peng G, Luo B, Li J, Zhao D, Wu W, Chen F, Chen Z: Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients. J Clin Immunol 2011, 31:195-204.
• [32]Serinoz E, Varli M, Erden E, Cinar K, Kansu A, Uzunalimoglu O, Yurdaydin C, Bozkaya H: Nuclear localization of hepatitis B core antigen and its relations to liver injury, hepatocyte proliferation, and viral load. J Clin Gastroenterol 2003, 36:269-272.
• [33]Wang GQ, Ding YP, Dong YH: Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat 2013, 20(Suppl 1):9-17.
• [34]Fujimoto K, Endo T, Nishio M, Obara M, Yamaguchi K, Takeda Y, Goto H, Kasahara I, Sato N, Koike T: Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier. Int J Hematol 2009, 90:601-604.
• [35]Wang F, Yuan S, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, Rao HL, Xia Y, Jiang WQ, Huang HQ, et al.: High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev 2012, 21:261-267.